High Drug Prices Questioned By Medicaid Plans, AARP And Others

The focus was on hepatitis C drugs, new biologics, cholesterol drugs, and breakthrough drugs that have yet to be invented as leaders representing Medicaid directors, AARP and others recently met for a Campaign for Sustainable Rx Pricing panel to discuss how their sectors are being affected by high drug prices. Peter Bach, director of the Center for Health Policy and Outcomes at the Memorial Sloan Kettering Cancer Center, pointed to Gilead Sciences, which he said ended up dropping the price...